{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:15599"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:15599","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Hormonal regulation of skeletal muscle metabolism","abstract":"Nicotinamide Adenine Dinucleotide (NAD+) is a cofactor for enzymes serving cellular metabolic reactions and a consumed substrate for sirtuins and poly (adenosine diphosphate-ribose) polymerases (PARPs), enzymes that regulate protein deacetylation and DNA repair, and translate changes in energy and cell status into metabolic adaptations. Deranged NAD+ homeostasis and concurrent mitochondrial dysfunction are key features of ageing and age-related metabolic disease. Contemporary NAD+ precursors (vitamin B3 derivatives) showed promise as therapeutic nutraceuticals to restore target tissue NAD+ in at risk groups and have demonstrated improvements in mitochondrial function and sirtuin-dependent signalling in pre-clinical studies. We conducted the NADMet (Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype) clinical study to examine whether NAD+ can be increased in human tissues using oral nutraceutical approaches and assess for a potential role in combating metabolic disease and the unwanted effects of ageing. The results showed that the oral supplementation of the NAD+ precursor, nicotinamide riboside, in aged men was safe and well-tolerated leading to an increase in the skeletal muscle NAD+ metabolome and induced a specific transcriptomic signature without altering muscle specific or systemic metabolism. NAD+ is also a parent molecule for NADPH which is a cofactor for the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme that regenerates glucocorticoids in the sarcoplasmic reticulum (SR) of skeletal muscle. The maintenance of the SR NADPH/NADP+ ratio is poorly understood. This work suggests a novel level of regulated glucocorticoid metabolism in skeletal muscle whereby 11β-HSD1 activity can be influenced by cellular redox status and NAD+ levels beyond the SR.","abstract_html":"Nicotinamide Adenine Dinucleotide (NAD+) is a cofactor for enzymes serving cellular metabolic reactions and a consumed substrate for sirtuins and poly (adenosine diphosphate-ribose) polymerases (PARPs), enzymes that regulate protein deacetylation and DNA repair, and translate changes in energy and cell status into metabolic adaptations. Deranged NAD+ homeostasis and concurrent mitochondrial dysfunction are key features of ageing and age-related metabolic disease. Contemporary NAD+ precursors (vitamin B3 derivatives) showed promise as therapeutic nutraceuticals to restore target tissue NAD+ in at risk groups and have demonstrated improvements in mitochondrial function and sirtuin-dependent signalling in pre-clinical studies. We conducted the NADMet (Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype) clinical study to examine whether NAD+ can be increased in human tissues using oral nutraceutical approaches and assess for a potential role in combating metabolic disease and the unwanted effects of ageing. The results showed that the oral supplementation of the NAD+ precursor, nicotinamide riboside, in aged men was safe and well-tolerated leading to an increase in the skeletal muscle NAD+ metabolome and induced a specific transcriptomic signature without altering muscle specific or systemic metabolism. NAD+ is also a parent molecule for NADPH which is a cofactor for the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme that regenerates glucocorticoids in the sarcoplasmic reticulum (SR) of skeletal muscle. The maintenance of the SR NADPH/NADP+ ratio is poorly understood. This work suggests a novel level of regulated glucocorticoid metabolism in skeletal muscle whereby 11β-HSD1 activity can be influenced by cellular redox status and NAD+ levels beyond the SR.","abstract_has_math":false,"creators":["Elhassan, Yasir"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-12","date_published":"2024-12","updated_at":"2026-11-19T09:32:59Z","subjects":["R Medicine (General)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/15599/12/Elhassan2024PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A15599","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["mrc"]},{"key":"dc:creator","label":"Author","values":["Elhassan, Yasir"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-12-09"]},{"key":"dc:date.issued","label":"Date","values":["2024-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Metabolism and Systems Research"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/15599/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["R Medicine (General)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/15599/12/Elhassan2024PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Nicotinamide Adenine Dinucleotide (NAD+) is a cofactor for enzymes serving cellular metabolic reactions and a consumed substrate for sirtuins and poly (adenosine diphosphate-ribose) polymerases (PARPs), enzymes that regulate protein deacetylation and DNA repair, and translate changes in energy and cell status into metabolic adaptations. Deranged NAD+ homeostasis and concurrent mitochondrial dysfunction are key features of ageing and age-related metabolic disease. Contemporary NAD+ precursors (vitamin B3 derivatives) showed promise as therapeutic nutraceuticals to restore target tissue NAD+ in at risk groups and have demonstrated improvements in mitochondrial function and sirtuin-dependent signalling in pre-clinical studies. We conducted the NADMet (Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype) clinical study to examine whether NAD+ can be increased in human tissues using oral nutraceutical approaches and assess for a potential role in combating metabolic disease and the unwanted effects of ageing. The results showed that the oral supplementation of the NAD+ precursor, nicotinamide riboside, in aged men was safe and well-tolerated leading to an increase in the skeletal muscle NAD+ metabolome and induced a specific transcriptomic signature without altering muscle specific or systemic metabolism. NAD+ is also a parent molecule for NADPH which is a cofactor for the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme that regenerates glucocorticoids in the sarcoplasmic reticulum (SR) of skeletal muscle. The maintenance of the SR NADPH/NADP+ ratio is poorly understood. This work suggests a novel level of regulated glucocorticoid metabolism in skeletal muscle whereby 11β-HSD1 activity can be influenced by cellular redox status and NAD+ levels beyond the SR."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Hormonal regulation of skeletal muscle metabolism"]}]}],"canonical_facts":{"dc:contributor.sponsor":["mrc"],"dc:creator":["Elhassan, Yasir"],"dc:date":["2024-12-09"],"dc:date.issued":["2024-12"],"dc:description.abstract":["Nicotinamide Adenine Dinucleotide (NAD+) is a cofactor for enzymes serving cellular metabolic reactions and a consumed substrate for sirtuins and poly (adenosine diphosphate-ribose) polymerases (PARPs), enzymes that regulate protein deacetylation and DNA repair, and translate changes in energy and cell status into metabolic adaptations. Deranged NAD+ homeostasis and concurrent mitochondrial dysfunction are key features of ageing and age-related metabolic disease. Contemporary NAD+ precursors (vitamin B3 derivatives) showed promise as therapeutic nutraceuticals to restore target tissue NAD+ in at risk groups and have demonstrated improvements in mitochondrial function and sirtuin-dependent signalling in pre-clinical studies. We conducted the NADMet (Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype) clinical study to examine whether NAD+ can be increased in human tissues using oral nutraceutical approaches and assess for a potential role in combating metabolic disease and the unwanted effects of ageing. The results showed that the oral supplementation of the NAD+ precursor, nicotinamide riboside, in aged men was safe and well-tolerated leading to an increase in the skeletal muscle NAD+ metabolome and induced a specific transcriptomic signature without altering muscle specific or systemic metabolism. NAD+ is also a parent molecule for NADPH which is a cofactor for the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme that regenerates glucocorticoids in the sarcoplasmic reticulum (SR) of skeletal muscle. The maintenance of the SR NADPH/NADP+ ratio is poorly understood. This work suggests a novel level of regulated glucocorticoid metabolism in skeletal muscle whereby 11β-HSD1 activity can be influenced by cellular redox status and NAD+ levels beyond the SR."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/15599/12/Elhassan2024PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Metabolism and Systems Research"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/15599/"],"dc:subject":["R Medicine (General)"],"dcterms:accessrights":["public"],"dc:title":["Hormonal regulation of skeletal muscle metabolism"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:32:59Z"}